CC-486
Drug
Celgene Corporation
Total Payments
$6.9M
Transactions
498
Doctors
99
Companies
1
Payment Trends by Year
| Year | Amount | Transactions | Doctors |
|---|---|---|---|
| 2019 | $1.5M | 115 | 32 |
| 2018 | $2.6M | 166 | 50 |
| 2017 | $2.8M | 217 | 68 |
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $6.9M | 468 | 99.8% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $12,000 | 4 | 0.2% |
| Food and Beverage | $1,838 | 25 | 0.0% |
| Consulting Fee | $1,050 | 1 | 0.0% |
Payments by Type
Research
$6.9M
468 transactions
General
$14,888
30 transactions
Research Studies & Clinical Trials
| Study Name | Sponsor | Amount | Doctors |
|---|---|---|---|
| CC-486-CAGEN-001 - A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects | Celgene Corporation | $1.0M | 0 |
| CC-486-DLBCL-001 | Celgene Corporation | $892,826 | 8 |
| CC-486-AML-001 | Celgene Corporation | $478,212 | 4 |
| PhIII Azacitidine AML Quazar CC-486-AML-001 (CC-486-AML-001) | Celgene Corporation | $427,802 | 4 |
| CC-486-MDS-006 - PhII CC-486 mono and combo with Durvalumab in MDS Post HMA failures ) | Celgene Corporation | $374,181 | 0 |
| CC-486-NSCL-001 | Celgene Corporation | $339,139 | 3 |
| CC-486-CAGEN-001 | Celgene Corporation | $323,448 | 0 |
| Phase II Study of CC486-CHOP for Previously Untreated Peripheral T-cell Lymphoma (OA-CL-PTCL-PI-13043) | Celgene Corporation | $242,692 | 0 |
| PhII CC-486 mono and combo with Durvalumab in MDS Post HMA failures ) (CC-486-MDS-006) | Celgene Corporation | $231,213 | 0 |
| Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer (CC-486-NSCL-001) | Celgene Corporation | $230,230 | 0 |
| CC-486-AML-001 - PhIII Azacitidine AML Quazar CC-486-AML-001 | Celgene Corporation | $195,851 | 0 |
| CC-486-DLBCL-001 - (AZA-JMML-001) PhII Azacitidine Open-label PK, Pharmacodynamics, Safety, Activity vs Historical Controls in Peds With ND Advanced MDS | Celgene Corporation | $184,758 | 6 |
| OA-CL-MEL-PI-006359 | Celgene Corporation | $180,149 | 0 |
| OA-CL-MEL-PI-006359 - Phase I/II Study of Oral Azacitidine (CC-486) in Combination with Pembrolizumab (MK-3475) in Patients with Metastatic Melanoma | Celgene Corporation | $162,500 | 0 |
| CC-486-MDS-006 | Celgene Corporation | $150,507 | 0 |
| CC-486-NSCL-001 - Safety and Efficacy Study of CC-486 With MK-3475 to Treat Locally Advanced or Metastatic Non-small Cell Lung Cancer | Celgene Corporation | $145,768 | 3 |
| A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects (CC-486-CAGEN-001) | Celgene Corporation | $137,367 | 10 |
| AZA-MDS-003 | Celgene Corporation | $129,160 | 0 |
| CC-486-AML-002 | Celgene Corporation | $85,216 | 7 |
| (AZA-JMML-001) PhII Azacitidine Open-label PK, Pharmacodynamics, Safety, Activity vs Historical Controls in Peds With ND Advanced MDS (CC-486-DLBCL-001) | Celgene Corporation | $82,979 | 0 |
Top Doctors Receiving Payments for CC-486
| Doctor | Specialty | Location | Total | Records |
|---|---|---|---|---|
| Unknown | — | New York, NY | $6.4M | 331 |
| , MD | Medical Oncology | Boston, MA | $40,937 | 3 |
| Bart Scott | Medical Oncology | Seattle, WA | $24,431 | 7 |
| , MD | Medical Oncology | Gainesville, FL | $17,501 | 5 |
| , M.D | Medical Oncology | West Palm Beach, FL | $13,450 | 1 |
| , M.D | Hematology & Oncology | Nashville, TN | $13,272 | 4 |
| , M.D | Medical Oncology | Houston, TX | $13,143 | 4 |
| , M.D | Hematology & Oncology | Cleveland, OH | $11,140 | 3 |
| , MD | Hospitalist | Columbus, OH | $10,664 | 2 |
| , M.D | Internal Medicine | Houston, TX | $10,664 | 2 |
| , M.D | Hematology & Oncology | New York, NY | $10,664 | 2 |
| , M.D | Hematology & Oncology | Houston, TX | $10,664 | 2 |
| , MD00022875 | Hematology & Oncology | Yakima, WA | $8,813 | 3 |
| , MD | Hematology | New York, NY | $8,376 | 2 |
| , MD | Internal Medicine | New York, NY | $7,736 | 5 |
| , MD | Hematology & Oncology | Aurora, CO | $7,224 | 3 |
| , MD | Internal Medicine | Ann Arbor, MI | $7,224 | 3 |
| , MD | Hematology & Oncology | Kansas City, MO | $7,133 | 2 |
| , MD, PHD | Hematology & Oncology | Racine, WI | $6,807 | 3 |
| , M.D | Hematology & Oncology | Houston, TX | $6,512 | 4 |
| , M.D | Hematology & Oncology | Boston, MA | $6,486 | 2 |
| , M.D | Hematology | Cincinnati, OH | $6,486 | 2 |
| , MD | Hematology | Evanston, IL | $6,486 | 2 |
| , MD | Hematology & Oncology | Cleveland, OH | $6,486 | 2 |
| , MD | Hematology & Oncology | Greenville, SC | $6,453 | 3 |
Ad
Manufacturing Companies
- Celgene Corporation $6.9M
Product Information
- Type Drug
- Total Payments $6.9M
- Total Doctors 99
- Transactions 498
About CC-486
CC-486 is a drug associated with $6.9M in payments to 99 healthcare providers, recorded across 498 transactions in the CMS Open Payments database. The primary manufacturer is Celgene Corporation.
Payment data is available from 2017 to 2019. In 2019, $1.5M was paid across 115 transactions to 32 doctors.
The most common payment nature for CC-486 is "Unspecified" ($6.9M, 99.8% of total).
CC-486 is associated with 20 research studies, including "CC-486-CAGEN-001 - A Phase 1, Open-label, Multicenter, Randomized, 2-Period, Crossover Study to Evaluate the Bioequivalence and Food Effect Bioavailability of CC-486 (Oral Azacitidine) Tablets in Adult Cancer Subjects" ($1.0M).